Physician profile
Rodney Johnson
NPI 1992828289
$22,331.84
in general payments reported to CMS, 2019-2025
30 companies · $8,395 in 2025
The $8,395 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $553 · 2021: $988 · 2022: $1,750 · 2023: $1,702 · 2024: $8,589 · 2025: $8,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,519 · Travel and Lodging: $296 · Education: $147 · Consulting Fee: $74.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,650.00 |
| Food and Beverage | $6,518.84 |
| Travel and Lodging | $295.53 |
| Education | $146.76 |
| Consulting Fee | $74.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $14,082.79 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,280.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,173.99 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,093.57 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $670.25 | 2019-2025 | Xolair |
| Grifols USA, LLC | $581.82 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Octapharma USA, INC. | $567.25 | 2022-2025 | Cutaquig, Panzyga |
| Novartis Pharmaceuticals Corporation | $493.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.06 | 2020-2025 | Glassia, Cuvitru, Takhzyro |
| Csl Behring | $333.29 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Amgen INC. | $275.29 | 2022-2025 | Tezspire, Tepezza |
| Pfizer INC. | $220.42 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $158.83 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.81 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $120.57 | 2022-2025 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $115.75 | 2025 | Neffy |
| Kaleo, INC. | $99.04 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Leo Pharma INC. | $77.86 | 2022-2023 | Adbry |
| Adma Biomanufacturing LLC | $74.47 | 2023-2024 | |
| Hikma Pharmaceuticals USA | $68.97 | 2023-2025 | Ryaltris |
| Lundbeck LLC | $40.64 | 2025 | Vyepti |
| Pharming Healthcare, INC. | $29.87 | 2024 | Ruconest |
| Blueprint Medicines Corporation | $26.03 | 2024 | Ayvakit |
| Optinose US, INC. | $24.32 | 2024 | |
| Aimmune Therapeutics, INC. | $21.60 | 2021 | |
| Horizon Therapeutics Plc | $21.23 | 2020 | |
| Merck Sharp & Dohme LLC | $21.09 | 2021 | |
| Dermavant Sciences, INC. | $19.42 | 2024 | Vtama |
| Circassia INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.